Zacks Research Forecasts Longeveron FY2028 Earnings

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at Zacks Research issued their FY2028 EPS estimates for Longeveron in a report issued on Tuesday, February 17th. Zacks Research analyst B. Sorensen forecasts that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $6.50.

Longeveron Trading Down 0.3%

LGVN opened at $0.56 on Thursday. The company has a market capitalization of $11.94 million, a price-to-earnings ratio of -0.53 and a beta of 0.21. Longeveron has a 12-month low of $0.49 and a 12-month high of $1.92. The business’s fifty day simple moving average is $0.56 and its 200-day simple moving average is $0.71.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd purchased a new position in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.